ATV-1601

ATV-1601 is an orally bioavailable, selective allosteric small molecule inhibitor targeting the AKT1 E17K mutation. Developed by Atavistik Bio, it is designed for precision oncology applications, specifically for cancers driven by the AKT1 E17K mutation. The drug leverages Atavistik Bio’s AMPS technology and AI-enabled drug discovery platform to achieve enhanced target inhibition, superior efficacy, and improved tolerability compared to pan-AKT inhibitors. Preclinical studies have demonstrated potent and durable tumor regressions in patient-derived xenograft models of AKT1 E17K-driven cancers with high target engagement. The primary indication under development is solid tumors harboring the AKT1 E17K mutation[2][5][10].